| Gene | AMOTL1L | Organism | Human |
| Genome Locus | | Build | hg19 |
| Disease | Prostate Cancer | ICD-10 | Malignant neoplasm of prostate (C61) |
| DBLink | | PMID | 30531834 |
| Experimental Method |
| Sample Type | Tissue and cell lines | Comparison | Patients (median age 65 years, range 52 to 79) underwent radical prostatectomy for localized PCa (n"‰="‰62) and benign prostatic hyperplasia (n"‰="‰35) underwent transurethral resection of the prostate (TURP)
|
| Method for Estimation | Quantitative PCR and Microaarays | PCR Details | |
Primers
| No Primers Found | Statistics | Fold Change : Downregulated
pvalue : <0.05 |
| Citation |
| Yang, Z, Qu, CB, Zhang, Y, Zhang, WF, Wang, DD, Gao, CC, Ma, L, Chen, JS, Liu, KL, Zheng, B, Zhang, XH, Zhang, ML, Wang, XL, Wen, JK, Li, W (2019). Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene, 38, 14:2516-2532. |
